Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc's clinical-stage programs, particularly GRI-0621 and GRI-0803, showcase promising data, with interim results indicating improvements in lung function and serum biomarkers, suggesting efficacy in addressing fibrotic and autoimmune disorders. The company's current valuation appears attractive, with significant upside potential based on a net present value (NPV) analysis, reflecting the results of their ongoing clinical trials. Positive interim data along with a well-tolerated treatment regimen further bolster the prospects for growth, highlighting GRI Bio's potential in the biotech sector.

Bears say

GRI Bio Inc. reported a net loss of $3.4 million for the recent quarter, with an earnings per share (EPS) of $(1.28), which was worse than both the analyst estimates and consensus expectations. The company faces significant risks, including balance sheet and liquidity challenges, the potential failure of its product candidates in clinical trials, and the need to secure regulatory approvals and reimbursement, all of which could hinder its ability to commercialize its therapies successfully. Despite the potential for substantial market opportunities, the long development timelines and high risks associated with clinical and commercial failures contribute to a negative financial outlook for the company's stock.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.